v3.26.3
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Cash flows used in operating activities:    
Net loss $ (27,364) $ (14,566)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 202 261
Share-based compensation 542 576
Impairment charges 0 2,783
Amortization of acquired in-process research and development asset 4,947 0
Amortization of clinical trial services asset 167 0
Remeasurement of earnout liability 0 (608)
Amortization of discount and issuance costs of convertible note 1,749 0
Warrant and derivative liabilities issuance cost 113 0
Change in fair value of warrant and derivative liabilities 5,041 0
Exchange rate fluctuations 9 (103)
Changes in assets and liabilities:    
Trade receivables, net (1,511) (122)
Prepaid expenses and other assets (638) (208)
Operating lease right-of-use assets 246 327
Inventories (1,116) (465)
Trade payables 690 (300)
Employees and payroll accruals 71 (80)
Deferred revenues 131 (199)
Operating lease liabilities (253) (643)
Other liabilities 910 76
Net cash used in operating activities (16,064) (13,271)
Cash flows used in investing activities:    
Purchase of property and equipment (8) (5)
Cash paid in connection with the acquisition of Skelable [1] (20) 0
Net cash used in investing activities (28) (5)
Cash flows from financing activities:    
Issuance of ordinary shares in a “registered direct” offering, net of issuance expenses in the amount of $558 [2] 0 4,442
Issuance of ordinary shares under at-the-market offering, net of issuance costs of $162 [2] 0 1,774
Issuance of ordinary shares in a public offering, net of issuance expenses in the amount of $391 [2] 0 2,209
Cash acquired in connection with the acquisition of Oratech [1],[3] 6,500 0
Net proceeds from issuance of Additional Notes [4],[5] 1,025 0
Net proceeds from issuance of New Notes [5],[6] 1,955 0
Net proceeds from issuance of derivative liabilities [5],[6] 1,820 0
Net proceeds from issuance of warrant liabilities [5],[6] 1,622 0
Net proceeds from issuance of July Note derivative liabilities [6],[7] 2,972 0
Net proceeds from issuance of July Note warrant liabilities [6],[7] 2,598 0
Net proceeds from issuance of July Note [6],[7] 10 0
Net cash provided by financing activities 18,502 8,425
Effect of Exchange rate changes on Cash, Cash Equivalents and Restricted Cash (9) 103
Increase (decrease) in cash, cash equivalents, and Restricted cash 2,401 (4,748)
Cash, cash equivalents, and restricted cash at beginning of period 2,579 7,108
Cash, cash equivalents, and restricted cash at end of period 4,980 2,360
Supplemental disclosures of non-cash flow information    
Classification of inventory to property and equipment, net 40 30
ROU assets obtained from lease liabilities [2] 1,143 0
Recognition of warrant liability upon issuance of New Notes 1,175 0
Recognition of derivative liability associated with New Notes 1,317 0
Expenses related to offerings not yet paid [2] 0 529
Supplemental cash flow information:    
Cash and cash equivalents 4,548 1,956
Restricted cash 432 404
Total Cash, cash equivalents, and Restricted cash $ 4,980 $ 2,360
[1] See Note 6.
[2] See Note 8f.
[3] Represents cash acquired in connection with the acquisition of Oratech from Oramed Pharmaceuticals Inc., a related party, of $6,500.
[4] Represents proceeds from issuance of Additional Notes to Oramed Pharmaceuticals Inc., a related party, of $1,025 for the six months ended June 30, 2026.
[5] See Note 9a.
[6] Includes proceeds from issuance of New Notes, derivative liabilities and warrant liabilities to Oramed Pharmaceuticals Inc., a related party, of $4,397 for the six months ended June 30, 2026.
[7] See Note 9b.